NetScientific PLC Bob Englert Appointed CEO of Vortex Biosciences (4154Q)
06 Junho 2018 - 3:01AM
UK Regulatory
TIDMNSCI
RNS Number : 4154Q
NetScientific PLC
06 June 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
NetScientific portfolio company Vortex Biosciences appoints Bob
Englert as Chief Executive Officer
London, UK - 6(th) June 2018 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation Group, announces that its portfolio company
Vortex Biosciences has appointed Bob Englert as Chief Executive
Officer.
Bob, who is currently Chief Technology Officer, takes up the
position with immediate effect, replacing Gene Walther, who has
been Chief Executive Officer of Vortex Biosciences since January
2016. Gene has resigned to pursue other interests and will be
stepping down from his position as Chief Executive Officer and
Member of the Board.
Bob Englert, who has been Chief Technology Officer of Vortex
since 2016, has over 25 years of global experience in medical
devices and life sciences, with a particular focus on IVD, Point of
Care, and digital health solutions. Before joining Vortex, he has
served as CEO and Founder of Biomedtrics Inc., a diabetes data
management company, where he raised funding and commercialized a
mobile medical data device. Prior to that he was COO of Pelikan
Technologies, a Point of Care glucose testing company. Earlier in
his career, Bob held multiple senior roles at Abbott Laboratories.
Bob has a Bachelor of Science Degree in Biology from the University
of Illinois Urbana-Champaign.
Vortex has also appointed Steve Crouse, who has been Chief
Commercial Officer since March 2016, to the position of Chief
Operating Officer. Steve, who has significant experience in medical
diagnostics, instruments development, and medical marketing, will
work closely with Bob and the Board to drive R&D and
commercialisation strategies. Steve was previously Senior VP of
Sales and Marketing at Freeslate, a company focused on providing
laboratory automation to Chemical and Pharmaceutical companies.
François R. Martelet, Chief Executive Officer of NetScientific
and Chairman of Vortex Biosciences, commented: "Vortex is
approaching a critical commercialisation phase with its unique CTC
isolation technology, and Bob is in a unique position to drive this
forward. With expertise gained from his role as Chief Technology
Officer and underpinned by years of industry experience,
particularly in the diagnostics field, we believe he is the right
person to take Vortex through the next phase of its growth.
"I would also like to thank Gene Walther for his contribution to
the Company during its formative years, and we wish Gene all the
best for the future."
Bob Englert, incoming Chief Executive Officer of Vortex
Biosciences, said: "Vortex Biosciences has developed a CTC
isolation and enrichment technology that is superior to other
products and is positioned to fundamentally improve the
capabilities of researchers and clinicians to identify cancer cells
utilizing a non-invasive liquid biopsy sample. I look forward to
continuing the impressive progress that the team at Vortex has made
in bringing this product to market."
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite, CFO
Consilium Strategic Communications
Mary-Jane Elliott Jessica Hodgson Tel: +44 (0)20 3709 5700
/ netscientific@consilium-comms.com
Chris Welsh / Laura Thornton
Stifel Nicolaus Europe Limited Tel: +44 (0) 20 7710 7600
(NOMAD and Broker)
Jonathan Senior / David Arch
/ Ben Maddison
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
About Vortex Biosciences
Vortex Biosciences is a leader in liquid biopsy solutions with a
mission to revolutionize cancer diagnosis, monitoring and treatment
by replacing tissue biopsies with simple blood tests. As a first
step in achieving this mission, they have introduced the VTX-1
Liquid Biopsy System. The VTX-1 instrument harvests intact
circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification, monitoring disease progression and drug treatment
effectiveness. Vortex is a core subsidiary of NetScientific plc, a
transatlantic healthcare technology group with an investment
strategy focused on sourcing, funding and commercializing
technologies that significantly improve the health and well-being
of people with chronic diseases. For more information, visit
http://www.vortexbiosciences.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALLFSDRIIEIIT
(END) Dow Jones Newswires
June 06, 2018 02:01 ET (06:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024